
LVTX Stock Forecast & Price Target
LVTX Analyst Ratings
Bulls say
LAVA Therapeutics NV is projected to significantly increase its revenue, with risk-adjusted earnings for LAVA-1266 expected to grow from $16 million in 2031 to $58 million by 2034, showing promising potential as the company advances its clinical programs. The collaborations with major pharmaceutical partners, Pfizer and Johnson & Johnson, are anticipated to provide substantial non-dilutive funding and support for LAVA's proprietary pipeline, emphasizing the strategic advantage of these partnerships. Furthermore, recent clinical data indicates that LAVA's products are safe, well-tolerated, and demonstrate early efficacy signals, which collectively bolster the positive outlook for the company's future growth and development in the immuno-oncology sector.
Bears say
LAVA Therapeutics NV has reported no revenue for the third quarter of 2024 and experienced a net loss of $0.46 per share, which exceeded the consensus estimate of a net loss of $0.35 per share. The company faces significant uncertainty regarding its sole clinical asset, LAVA-1266, which may be deprioritized due to the ongoing strategic review aimed at extending cash reserves. Additionally, a recent workforce reduction of approximately 30% highlights the company's challenges in a difficult market environment, contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of LAVA Therapeutics NV and is not a guaranteed prediction by Public.com or investment advice.
LVTX Analyst Forecast & Price Prediction
Start investing in LVTX
Order type
Buy in
Order amount
Est. shares
0 shares